Angiex
Health Care · Biologics & Biosimilars
$24.9Mtotal raised · 2 rounds on record
$22Mlatest round · Venture round · Jul 2025 · 15 mo ago
1backers · K5 Global
200+team · employees, estimated range
Overview
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality.
Funding and backers
Total raised
$24.9M
2 rounds on record
Latest round
$22M
Venture round · Jul 2025 · 15 mo ago
Team
201-500
employees, estimated range
Backers
1
K5 Global
The money's age
Due for its next round
15 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Aug 27
Partnership Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate Using Signatera - Company Announcement · markets.ft.com
Jul 31, 2025
Raised a round Venture round $22M · SEC Form D
Nov 2, 2023
Certified Angiex Announces FDA Clearance of IND Application for AGX101, a novel, First-in-Class TM4SF1-Directed Antibody-Drug Conjugate for the Treatment of So… · YahooFinance
Jul 3, 2017
Raised a round Venture round $2.9M · SEC Form D
2015
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Jul 2025 | $22M | — | SEC Form D |
| Venture round | Jul 2017 | $2.9M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Angiex, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Paul JaminetExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
THE CLAUDIN-1 COMPANY Treat cancer and reverse fibrosis We are a clinical-stage biotech company with a mission to treat cancer and reverse…
Home Technology Antibody Drug Conjugates Innovative Platform - ‘OptiLinked’ FDCs Additional Products & Applications ANT-045, Antikor’s…
Novel ADC Payloads for Cancer Hexagon Bio is developing novel payload mechanisms for antibody-drug conjugates (ADCs) to overcome resistance…
EnteroBiotix is a clinical-stage biopharmaceutical company developing best-in-class full-spectrum microbial therapeutics.
About the technology. Optimeos is developing a solution suite to overcome crucial formulation challenges and address unmet medical needs.
Neurolieve Biosciences is developing NLV-01, a first-in-class, non-opioid biologic designed to silence neuropathic pain and trigger…
People
Paul Jaminet
Executive Officer, Director
Jonathan Adams
Director
Errik Anderson
Director
Jason Camm
Director
Fabian Hansen
Director
Amal Amin
Director
Haijing Guo
Director
Iain Dukes
Director
Tina Neel
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
K5 GlobalVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Natera & Angiex Partner to Evaluate AGX101 Response With Signatera
NTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen insights into treatment response.
Read more
Report
Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate Using Signatera - Company Announcement - FT.com
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Read more
Report
Angiex Announces First Patient Dosed in Phase 1 Clinical Trial of AGX101, a novel TM4SF1-Directed Antibody-Drug Conjugate for the Treatment of Solid Tumors
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- August 7, 2024: Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) therapies for solid cancers, announced that the first patient has been dosed in the Phase 1 clinical trial of AGX
Read more
Report
Angiex Announces FDA Clearance of IND Application for AGX101, a novel, First-in-Class TM4SF1-Directed Antibody-Drug Conjugate for the Treatment of Solid Cancers
CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) therapies for solid cancers, announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational
Read more
Report
Spoločnosť Merck spolupracuje s firmou Angiex pri urýchlení klinickej pripravenosti novej onkologickej liečby
/PRNewswire/ -- Merck, popredná vedecká a technologická spoločnosť dnes ohlásila spoluprácu s novým partnerom, spoločnosťou Angiex, Inc., Cambridge,...
Read more
Report
Merck Collaborates with Angiex to Speed Clinical Readiness of New Cancer Therapy
Collaboration gives Angiex access to Merck
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Cambridge
United States
HQ
Drug treatment
200-500 est. staff